What This Bill Does · Plain English
Summary
Plain-English summary not yet available for this bill. Check back after our next analysis run.
Action Timeline
2025-11-28
Introduced in House
2025-11-28
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdicti
2025-11-28
Introduced in House
Frequently Asked Questions
Did HR.6321 pass?
HR.6321 is still alive. Current stage: COMMITTEE. Pass likelihood: pending.
Who sponsored HR.6321?
HR.6321 was sponsored by Josh Gottheimer (D-New Jersey).
Full Bill Text
119 HR 6321 IH: Lung Cancer Medicare Access to Precise Testing Act U.S. House of Representatives 2025-11-28 text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. I 119th CONGRESS 1st Session H. R. 6321 IN THE HOUSE OF REPRESENTATIVES November 28, 2025 Mr. Gottheimer (for himself and Mrs. Kiggans of Virginia ) introduced the following bill; which was referred to the Committee on Energy and Commerce , and in addition to the Committee on Ways and Means , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned A BILL To amend title XVIII of the Social Security Act to require coverage of lung cancer biomarker testing under the Medicare program. 1. Short title This Act may be cited as the Lung Cancer Medicare Access to Precise Testing Act . 2. Requiring coverage of lung cancer biomarker testing under Medicare (a) Coverage Section 1861 of the Social Security Act ( 42 U.S.C. 1395x ) is amended— (1) in subsection (s)(2)— (A) in subparagraph (JJ), by adding and at the end; and (B) by adding at the end the following new subparagraph: (KK) lung cancer biomarker testing (as defined in subsection (nnn)); ; and (2) by adding at the end the following new subsection: (nnn) Lung cancer biomarker testing The term lung cancer biomarker testing means a test furnished on or after January 1, 2027, to an individual diagnosed with lung cancer for the identification of 1 or more specific biomarkers (such as genes, proteins, or other molecules) based on the analysis of such individual’s tissue, blood, or bodily fluids. . (b) Payment Section 1833(a)(1) of the Social Security Act ( 42 U.S.C. 1395y(a)(1) ) is amended— (1) by striking and (HH) and inserting (HH) ; and (2) by inserting , and (II) with respect to lung cancer biomarker testing (as defined in section 1861(nnn)), the amount paid shall be 100 percent of the reasonable charges for such testing before the semicolon at the end.
Loading intelligence layer…